{"id":44468,"date":"2022-05-30T17:01:27","date_gmt":"2022-05-30T15:01:27","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/advanced-hepatocellular-carcinoma-pipeline-market-research-report-2022-comprehensive-insights-about-50-companies-and-50-pipeline-drugs-researchandmarkets-com\/"},"modified":"2022-05-30T17:01:27","modified_gmt":"2022-05-30T15:01:27","slug":"advanced-hepatocellular-carcinoma-pipeline-market-research-report-2022-comprehensive-insights-about-50-companies-and-50-pipeline-drugs-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/advanced-hepatocellular-carcinoma-pipeline-market-research-report-2022-comprehensive-insights-about-50-companies-and-50-pipeline-drugs-researchandmarkets-com\/","title":{"rendered":"Advanced Hepatocellular Carcinoma Pipeline Market Research Report 2022: Comprehensive Insights about 50+ Companies and 50+ Pipeline Drugs – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Advanced Hepatocellular Carcinoma – Pipeline Insight, 2022”<\/a> drug pipelines has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThis “Advanced Hepatocellular Carcinoma- Pipeline Insight, 2022” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Advanced Hepatocellular Carcinoma pipeline landscape.\n<\/p>\n

\nIt covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.\n<\/p>\n

\n“Advanced Hepatocellular Carcinoma- Pipeline Insight, 2022” report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Advanced Hepatocellular Carcinoma pipeline landscape is provided which includes the disease overview and Advanced Hepatocellular Carcinoma treatment guidelines.\n<\/p>\n

\nThe assessment part of the report embraces, in depth Advanced Hepatocellular Carcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced Hepatocellular Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.\n<\/p>\n

\nReport Highlights<\/strong>\n<\/p>\n

\nThe companies and academics are working to assess challenges and seek opportunities that could influence Advanced Hepatocellular Carcinoma R&D. The therapies under development are focused on novel approaches to treat\/improve Advanced Hepatocellular Carcinoma.\n<\/p>\n

\nAdvanced Hepatocellular Carcinoma Emerging Drugs Chapters<\/strong>\n<\/p>\n

\nThis segment of the Advanced Hepatocellular Carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.\n<\/p>\n

\nAdvanced Hepatocellular Carcinoma Emerging Drugs<\/strong>\n<\/p>\n

\nTivozanib : AVEO Oncology\n<\/p>\n

\nFOTIVDA (tivozanib) is an oral, once-daily, differentiated vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). It is a potent, selective inhibitor of VEGFRs 1, 2, and 3 with a long half-life designed to improve efficacy and tolerability. Tivozanib has been shown to significantly reduce regulatory T-cell production in preclinical models. Currently, Tivozanib is being evaluated in Phase I\/II stage of clinical trial evaluation for the treatment of advanced hepatocellular carcinoma.\n<\/p>\n

\nNofazinlimab: CStone Pharmaceuticals\n<\/p>\n

\nCS1003 is a humanized recombinant IgG4 monoclonal antibody targeting human programmed cell death protein 1 (PD-1) being developed for immunotherapy of various tumors. Compared to most of the monoclonal antibodies that bind human and monkey PD-1(either already approved or in clinical stage) , CS1003 demonstrates comparable high binding affinities across species against human, cynomolgus monkey and mouse PD-1, and is developed to disrupt the interaction of PD-1 with its ligands PD-L1 and PD-L2 . CS1003 is also unique in that it can simultaneously recognize human and mouse PD-1, which allows fast pre-clinical proof of concept for CS1003 in combination with novel targeted therapies using syngeneic mouse tumor models. Currently, the drug is being developed in Phase III stage of development for the treatment of advanced hepatocellular carcinoma.\n<\/p>\n

\nECT 204: Eureka Therapeutics\n<\/p>\n

\nECT204, a GPC3 targeting ARTEMIS T-cell therapy for the treatment of hepatocellular carcinoma (HCC), the predominant type of liver cancer. Glypican 3 (GPC3) is a promising target for HCC therapies and is found in more than 70% of HCC cells. The GPC3 protein is also expressed in other solid tumors including ovarian and lung cancer. Currently, the drug is in Phase I\/II stage of Clinical trial evaluation for the treatment of advanced hepatocellular carcinoma.\n<\/p>\n

\nSintilimab:\n<\/p>\n

\nSintilimab is an immunoglobulin G4 monoclonal antibody, which binds to PD-1 molecules on the surface of T-cells, blocks the PD-1 \/ PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells. Innovent is currently conducting more than 20 clinical studies of sintilimab worldwide, to evaluate its safety and efficacy in a wide variety of cancer indications, including more than 10 registrational or pivotal clinical trials. Sintilimab, marketed as TYVYT (sintilimab injection) in China, is an innovative PD-1 inhibitor with global quality standards jointly developed by Innovent and Eli Lilly and Company. Currently, the drug is being developed in Phase I stage of Clinical trial evaluation for the treatment of advanced hepatocellular carcinoma.\n<\/p>\n

\nAdvanced Hepatocellular Carcinoma: Therapeutic Assessment<\/strong>\n<\/p>\n

\nThis segment of the report provides insights about the different Advanced Hepatocellular Carcinoma drugs segregated based on following parameters that define the scope of the report, such as:\n<\/p>\n

\nMajor Players in Advanced Hepatocellular Carcinoma<\/strong>\n<\/p>\n

\nThere are approx. 50+ key companies which are developing the therapies for Advanced Hepatocellular Carcinoma. The companies which have their Advanced Hepatocellular Carcinoma drug candidates in the most advanced stage, i.e. phase III include, CStone Pharmaceuticals.\n<\/p>\n

\nKey Questions Answered<\/strong>\n<\/p>\n